# Phase 3 endometrial cancer trials recruiting: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials in phase 3 for endometrial cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 endometrial cancer trials: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/endometrial-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 9, 2026 | NCT07867002 | Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer | UNC Lineberger Comprehensive Cancer Center | Phase 3 | Recruiting | Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867002) |
| October 6, 2026 | NCT07860450 | Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Endometrial Carcinoma, Neoplasms, Endometrial | 378 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860450) |
| September 21, 2026 | NCT07831902 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With... | University College, London | Phase 3 | Recruiting | Endometrial Cancer, Uterine Neoplasms | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831902) |
| July 6, 2026 | NCT07684599 | A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Endometrial | 610 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684599) |
| May 11, 2026 | NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With... | Pfizer | Phase 3 | Recruiting | Endometrial Neoplasms, Endometrial Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578649) |
| December 16, 2025 | NCT07286331 | A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based... | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Endometrial | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286331) |
| September 30, 2025 | NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy... | National Cancer Institute (NCI) | Phase 3 | Recruiting | Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07198074) |
| September 10, 2025 | NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Genmab | Phase 3 | Recruiting | Endometrial Cancer, Recurrent or Progressive Endometrial Cancer | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166094) |
| June 30, 2025 | NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | AstraZeneca | Phase 3 | Recruiting | Endometrial Cancer, Malignant Solid Tumour | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044336) |
| June 15, 2025 | NCT07022483 | A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant... | Daiichi Sankyo | Phase 3 | Recruiting | Endometrial Cancer | 710 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07022483) |
| May 25, 2025 | NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of... | AstraZeneca | Phase 3 | Recruiting | Endometrial Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06989112) |
| May 1, 2025 | NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Endometrial Cancer | 1,123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952504) |
| December 2, 2024 | NCT06712472 | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | Recruiting | Endometrial Cancer, p53abn | 554 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712472) |
| September 4, 2024 | NCT06584032 | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer | Hutchmed | Phase 3 | Recruiting | Advanced Endometrial Cancer | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06584032) |
| June 26, 2024 | NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Endometrial Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06475599) |
| April 1, 2024 | NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | BioNTech SE | Phase 3 | Recruiting | Endometrial Cancer | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06340568) |
| September 1, 2022 | NCT05524389 | Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant... | Peking Union Medical College Hospital | Phase 3 | Not yet recruiting | Endometrial Cancer, Adjuvant Radiotherapy, Molecular Classification | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05524389) |
| February 24, 2022 | NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features | Leiden University Medical Center | Phase 3 | Recruiting | Endometrial Cancer | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05255653) |
| March 9, 2021 | NCT04789694 | Prehabilitation in Gynaecological Cancer Patients | Charles University, Czech Republic | Phase 3 | Recruiting | Ovarian Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Endometrial Cancer, Frailty | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04789694) |
| August 29, 2019 | NCT04073706 | Sentinel Node Biopsy in Endometrial Cancer | Queensland Centre for Gynaecological Cancer | Phase 3 | Recruiting | Endometrial Cancer Stage I, Sentinel Lymph Node, Surgery | 760 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04073706) |
| December 24, 2018 | NCT03785288 | Vaginal Cuff Brachytherapy Fractionation Study | Sponsor not shown (see the record) | Phase 3 | Recruiting | Endometrial Cancer | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03785288) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| National Cancer Institute (NCI) | 1 |
| [Hutchmed](https://specstream.ai/data/clinical-trials/company/hutchmed) | 1 |
| Charles University, Czech Republic | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Peking Union Medical College Hospital | 1 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| University College, London | 1 |
| Queensland Centre for Gynaecological Cancer | 1 |
| Leiden University Medical Center | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 12 |
| Australia | 8 |
| Canada | 8 |
| China | 8 |
| France | 8 |
| Italy | 8 |
| Japan | 8 |
| Brazil | 7 |
| Germany | 7 |
| South Korea | 7 |
| Argentina | 6 |
| Belgium | 6 |
| Israel | 6 |
| Poland | 6 |
| Spain | 6 |
| Taiwan | 6 |
| United Kingdom | 6 |
| Czechia | 5 |
| Denmark | 5 |
| Finland | 5 |
| Greece | 5 |
| Netherlands | 5 |
| Singapore | 5 |
| Austria | 4 |
| Hungary | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fitness equipment wholesalers in the United States](https://specstream.ai/data/businesses/fitness-equipment-wholesalers/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
- [Aluminum suppliers in the United States](https://specstream.ai/data/businesses/aluminum-suppliers/united-states)
